Behavioral effects of flumazenil in the social conflict test in mice
Jazyk angličtina Země Německo Médium print-electronic
Typ dokumentu srovnávací studie, časopisecké články, práce podpořená grantem
- MeSH
- agrese účinky léků fyziologie MeSH
- flumazenil farmakologie MeSH
- konflikt (psychologie) * MeSH
- myši inbrední ICR MeSH
- myši MeSH
- pohybová aktivita účinky léků fyziologie MeSH
- sociální chování * MeSH
- zvířata MeSH
- Check Tag
- mužské pohlaví MeSH
- myši MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- srovnávací studie MeSH
- Názvy látek
- flumazenil MeSH
RATIONALE: Flumazenil, a competitive antagonist of benzodiazepine receptors (BZRs), has been used as a probe to detect effects of putative endogenous ligands for BZRs in anxiety. Flumazenil is renowned for its highly inconsistent behavioral effects. OBJECTIVE: To ascertain effects of flumazenil in the social conflict test in mice, which provides complex measures for prediction of anxiolytic and anxiogenic activity of drugs in behaviorally different groups of animals. METHODS: Singly housed male mice treated with flumazenil (5, 20 or 80 mg/kg i.p.) or vehicle were paired with untreated non-aggressive group-housed male mice in a novel cage. Behavior was analyzed from video tapes of the social interactions in three populations of mice: timid (n=21), aggressive (n=11), and sociable (n=7). Levels of gamma-aminobutyric acid (GABA) were measured in vivo in the prefrontal cortex. RESULTS: Flumazenil reduced timid (defensive-escape) and increased locomotor activities in timid mice. The drug reduced aggressive and increased sociable (social investigation) activities in aggressive mice. These behavioral changes were produced at the lowest dose of flumazenil tested (5 mg/kg) and were not increased further by higher doses of the drug (20 mg/kg or 80 mg/kg). A tendency to increased timidity was found after flumazenil in sociable mice. Concentrations of GABA were markedly higher in the prefrontal cortex of sociable mice than in timid or aggressive mice. CONCLUSIONS: Flumazenil produced moderate anxiolytic-like behavioural changes and a slight anxiogenic-like effect. The present data might be reflecting antagonism of corresponding endogenous BZR ligands. However, these putative ligands seem to exert only modest modulatory influence.
Zobrazit více v PubMed
Psychopharmacology (Berl). 1990;101(4):525-32 PubMed
Psychopharmacology (Berl). 1990;101(3):396-402 PubMed
Peptides. 1998;19(5):841-8 PubMed
Brain Res. 1984 Sep 17;310(1):154-6 PubMed
Neurochem Res. 2002 Dec;27(12):1605-12 PubMed
Pharmacol Rev. 1998 Jun;50(2):291-313 PubMed
Neuropharmacology. 1991 Dec;30(12A):1263-7 PubMed
Br J Pharmacol. 1979 Mar;65(3):525-33 PubMed
Brain Res Mol Brain Res. 2002 Jul 15;104(1):103-9 PubMed
Prog Clin Biol Res. 1984;167:93-114 PubMed
Physiol Behav. 2000 Dec;71(5):509-16 PubMed
Br J Pharmacol. 1992 Jan;105(1):164-70 PubMed
Pharmacol Biochem Behav. 1986 Mar;24(3):525-9 PubMed
Psychopharmacology (Berl). 1993;111(4):415-22 PubMed
Psychopharmacology (Berl). 1993;110(4):451-9 PubMed
Psychopharmacology (Berl). 1983;80(2):192-5 PubMed
J Neurosci. 1988 Jan;8(1):289-95 PubMed
Physiol Behav. 1984 Sep;33(3):401-9 PubMed
Psychopharmacology (Berl). 2001 Sep;157(2):123-30 PubMed
Peptides. 1992 Nov-Dec;13(6):1219-25 PubMed
Psychopharmacology (Berl). 1992;108(1-2):205-9 PubMed
Neurosci Biobehav Rev. 2001 May;25(3):205-18 PubMed
J Pharmacol Exp Ther. 1999 Sep;290(3):1222-9 PubMed
Psychopharmacology (Berl). 1992;108(1-2):196-204 PubMed
Psychopharmacology (Berl). 1993;111(2):144-52 PubMed
Neurosci Biobehav Rev. 1991 Winter;15(4):447-54 PubMed
Eur J Pharmacol. 1998 Oct 2;358(2):117-28 PubMed
Br J Pharmacol. 1975 Sep;55(1):141-50 PubMed
Psychopharmacology (Berl). 1986;90(2):278-80 PubMed
Behav Pharmacol. 1995 Nov;6(7):732-745 PubMed
Pharmacol Biochem Behav. 1999 Apr;62(4):727-34 PubMed
Arch Gen Psychiatry. 1990 Oct;47(10):917-25 PubMed
Psychopharmacology (Berl). 1999 Feb;142(1):85-94 PubMed
Brain Res Bull. 1988 May;20(5):603-6 PubMed
Anesthesiology. 1993 Dec;79(6):1183-92 PubMed
Life Sci. 1991;49(5):325-44 PubMed
Brain Res. 1991 Aug 23;557(1-2):167-76 PubMed
J Neurochem. 1992 Jun;58(6):2102-15 PubMed
Biol Psychiatry. 1999 Feb 1;45(3):321-6 PubMed
Neuropharmacology. 1982 Oct;21(10):1033-7 PubMed
Behav Pharmacol. 2000 Apr;11(2):143-51 PubMed
Neuropharmacology. 1991 Dec;30(12B):1387-9 PubMed
Psychopharmacology (Berl). 1986;89(4):395-403 PubMed
Psychopharmacology (Berl). 1976 Dec 21;51(1):75-80 PubMed
Proc Natl Acad Sci U S A. 1986 Feb;83(3):827-31 PubMed
Psychopharmacology (Berl). 1986;89(1):113-7 PubMed
Neuroscience. 1993 Dec;57(3):777-86 PubMed
Psychopharmacology (Berl). 2001 Apr;154(4):327-35 PubMed
Pharmacol Biochem Behav. 1993 Sep;46(1):161-5 PubMed
Physiol Behav. 2001 Nov-Dec;74(4-5):621-8 PubMed
Psychopharmacology (Berl). 2000 Jan;148(1):24-32 PubMed
Pharmacol Biochem Behav. 1985 Jul;23(1):17-20 PubMed
Acta Anaesthesiol Scand. 1990 Nov;34(8):628-31 PubMed